InnoCan PharmaHAM:IP40 +6.19%62 Altman Z-Score is -0.01 as of Jun. 29, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 62/100 and a GF Value™ of €9.62 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,931 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 91.51% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.03 is in distress zone. This implies bankruptcy possibility in the next two years.
InnoCan Pharma has a Altman Z-Score of -0.01, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for InnoCan Pharma's Altman Z-Score or its related term are showing as below:
HAM:IP40'
s Altman Z-Score Range Over the Past 10 Years
Min: -9.17 Med: 9.15 Max: 31.7
Current: 0.03
During the past 8 years, InnoCan Pharma's highest Altman Z-Score was 31.70. The lowest was -9.17. And the median was 9.15.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
InnoCan Pharma Altman Z-Score Related Terms
InnoCan Pharma Altman Z-Score Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IP40 vs PG, CL, KVUE: Altman Z-Score Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Altman Z-Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
InnoCan Pharma's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.8127
+
1.4
*
-3.412
+
3.3
*
-0.0704
+
0.6
*
2.8391
+
1.0
*
2.3172
=
-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
InnoCan Pharma (HAM:IP40) has a Altman Z-Score of -0.01 as of Jun. 29, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1767 out of 1931 companies in the Consumer Packaged Goods industry, placing it in the top 91.5%.
Is InnoCan Pharma's Altman Z-Score too high?
InnoCan Pharma's current Altman Z-Score is -0.01. Based on the distribution chart, InnoCan Pharma ranks #1767 out of 1931 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Altman Z-Score compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1767 out of 1931 companies for Altman Z-Score. This places InnoCan Pharma in the lower half of its industry. The industry median Altman Z-Score is 2.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Consumer Packaged Goods company?
The median Altman Z-Score among Consumer Packaged Goods companies is 2.83, based on 1,931 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Altman Z-Score is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Altman Z-Score is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.62, compared to a current price of €1.63 — trading 83.1% below its estimated fair value. The current Altman Z-Score is -0.01. InnoCan Pharma's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Altman Z-Score is -0.01 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.63 is trading 83.1% below its estimated GF Value™ of €9.62.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Altman Z-Score: -0.01
GF Value™: €9.62 vs. price of €1.63 (83.1% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
62GF Score
Get the complete analysis for HAM:IP40
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
